EVUSHELD

This brand name is authorized in Austria, Australia, Canada, Estonia, Ireland, Japan, Lithuania, Poland, Romania, United States

Active ingredients

The drug EVUSHELD contains a combination of these active pharmaceutical ingredients (APIs):

1 Tixagevimab
UNII F0LZ415Z3B - TIXAGEVIMAB
2 Cilgavimab
UNII 1KUR4BN70F - CILGAVIMAB

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
EVUSHELD Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J06BD03 J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BD Antiviral monoclonal antibodies
Discover more medicines within J06BD03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: CA Health Products and Food Branch Identifier(s): 02526271
Country: EE Ravimiamet Identifier(s): 1879926
Country: JP 医薬品医療機器総合機構 Identifier(s): 62505A1A1028
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1094411
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100466622
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W68715001
Country: US FDA, National Drug Code Identifier(s): 0310-1061, 0310-7442, 0310-8895

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.